New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:05 EDTEBSData from Phase IIb clinical trial for MVA85A published in The Lancet
Data were published in The Lancet from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin vaccine, the currently licensed and widely used TB vaccine. Data show that a single dose of MVA85A is not sufficient to confer statistically significant protection against TB disease or infection in infants who had been vaccinated at birth with BCG. There were 32 cases of TB disease in the infants that received BCG + MVA85A compared with 39 cases of disease among those receiving BCG + placebo. Non-significant vaccine efficacy was measured at 17.3%at study completion. The vaccine candidate also did not provide statistically significant protection from infection with Mycobacterium tuberculosis, the bacterium that causes TB, which was a secondary efficacy endpoint. The study was successful in that the vaccine was well tolerated, there was no evidence of any harm to the trial participants, and it gave a clear answer.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
09:20 EDTEBSEmergent BioSolutions task order shows capabilities, says Summer Street
Summer Street says the task order from the U.S. government regarding the manufacturing of ZMapp for treating Ebola shows Emergent BioSolutions' manufacturing capabilities and its working relationship with the government. The firm estimates the contract could be in the multi-$100M range and come as early as Q4, but admits it does not know who will win it. Summer Street views Emergent as undervalued and reiterates a Buy rating on the name with a $35 price target.
October 17, 2014
14:50 EDTEBSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use